title: Metabolic profile and cardiovascular risk factors among Latin American HIV-infected patients receiving HAART.
abstract: OBJECTIVE
  Determine the prevalence of metabolic abnormalities (MA) and estimate the 10-year risk for cardiovascular disease (CVD) among Latin American HIV-infected patients receiving highly active anti-retroviral therapy (HAART).
  
  
  METHODS
  A cohort study to evaluate MA and treatment practices to reduce CVD has been conducted in seven Latin American countries. Adult HIV-infected patients with at least one month of HAART were enrolled. Baseline data are presented in this analysis.
  
  
  RESULTS
  A total of 4,010 patients were enrolled. Mean age (SD) was 41.9 (10) years; median duration of HAART was 35 (IQR: 10-51) months, 44% received protease inhibitors. The prevalence of dyslipidemia and metabolic syndrome was 80.2% and 20.2%, respectively. The overall 10-year risk of CVD, as measured by the Framingham risk score (FRF), was 10.4 (24.7). Longer exposure to HAART was documented in patients with dyslipidemia, metabolic syndrome and type 2 diabetes mellitus. The FRF score increased with duration of HAART. Male patients had more dyslipidemia, high blood pressure, smoking habit and higher 10-year CVD than females.
  
  
  CONCLUSIONS
  Traditional risk factors for CVD are prevalent in this setting leading to intermediate 10-year risk of CVD. Modification of these risk factors through education and intervention programs are needed to reduce CVD.
authors.affiliation: Huésped Foundation, Buenos Aires, Argentina.
authors.forename: P
authors.initials: P
authors.lastname: Cahn
authors.forename: O
authors.initials: O
authors.lastname: Leite
authors.forename: A
authors.initials: A
authors.lastname: Rosales
authors.forename: R
authors.initials: R
authors.lastname: Cabello
authors.forename: C A
authors.initials: CA
authors.lastname: Alvarez
authors.forename: C
authors.initials: C
authors.lastname: Seas
authors.forename: C
authors.initials: C
authors.lastname: Carcamo
authors.forename: N
authors.initials: N
authors.lastname: Cure-Bolt
authors.forename: G P
authors.initials: GP
authors.lastname: L'Italien
authors.forename: P
authors.initials: P
authors.lastname: Mantilla
authors.forename: L
authors.initials: L
authors.lastname: Deibis
authors.forename: C
authors.initials: C
authors.lastname: Zala
authors.forename: T
authors.initials: T
authors.lastname: Suffert
mesh_terms: D000328:Adult; D019380:Anti-HIV Agents / Q000009:adverse effects*; D023241:Antiretroviral Therapy, Highly Active / Q000009:adverse effects*; D002318:Cardiovascular Diseases / Q000139:chemically induced*; D015331:Cohort Studies; D003924:Diabetes Mellitus, Type 2 / Q000139:chemically induced; D050171:Dyslipidemias / Q000139:chemically induced; D005260:Female; D015658:HIV Infections / Q000097:blood / Q000150:complications / Q000188:drug therapy*; D006801:Humans; D007843:Latin America; D008297:Male; D008659:Metabolic Diseases / Q000139:chemically induced*; D024821:Metabolic Syndrome / Q000139:chemically induced; D008875:Middle Aged; D012307:Risk Factors
chemical_list: D019380:Anti-HIV Agents